Surveillance, contact tracing and characteristics of SARS-CoV-2 transmission in educational settings in Northern Italy, September 2020 to April 2021Article Published on 2022-10-102022-11-16 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 변종, [키워드] Alpha variant Analysis attack rate calculated Characteristics Contact Contact tracing COVID-19 case Effectiveness elapsed identify implementation index case investigated Italy no difference occurred positive reduced remained risk of transmission SARS-CoV-2 SARS-CoV-2 transmission secondary secondary case Seven source of infection speed Spread study period surveillance data Swab test the epidemic Transmission virus was determined [DOI] 10.1371/journal.pone.0275667 PMC 바로가기
A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE networkArticle Published on 2022-10-082022-11-15 Journal: Trials [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] ≥75 years. adaptive addition advanced age age Analysis Antibody titre benefit BNT162b2 BNT162b2 (Comirnaty®) booster booster dose changes in Clinical course collected concern conducted COVID-19 COVID-19 pandemic COVID-19 vaccination COVID-19 vaccine dose Endpoint enzyme-linked immunosorbent evaluate exploratory fourth dose humoral immune response immunosenescence include individual initial Intervention mRNA-1273 mRNA-1273 (Spikevax®) multicentre neutralising neutralising antibody titre Older Part Patient performed phase phase II primary endpoint protocol qPCR Quantitative randomisation randomised randomised controlled reactogenicity Research risk factor SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine secondary subgroup T cell response the primary endpoint Trial triggered vaccination Vaccine vaccine-induced immune response variants variants of concern VoC wild-type wild-type virus [DOI] 10.1186/s13063-022-06791-y PMC 바로가기
Respondent Fatigue Reduces Dietary Diversity Scores Reported from Mobile Phone Surveys in Ethiopia during the COVID-19 PandemicArticle Published on 2022-10-062022-11-16 Journal: The Journal of Nutrition [Category] 비임상, [키워드] assigned collected comparison country COVID-19 COVID-19 pandemic decrease dietary dietary diversity Diversity Effect Ethiopia Ethiopian experiment fatigue FIVE fixed food group groups highlighting Impact information measure Metrics Mobile Older outcome phone survey Primary outcome question Randomized Randomly reported respondent response response fatigue. score secondary survey trade-off Volume were assessed women [DOI] 10.1093/jn/nxac153 PMC 바로가기
Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New EnglandArticle Published on 2022-10-032022-11-16 Journal: JAMA Network Open [Category] COVID19(2023년), SARS, 변종, [키워드] 30-Day mortality 95% CI accounted adjusted adjusted odds ratio Admission Admissions age Analysis appear applied approach assigned B.1.1.529 B.1.617.2 cohort study confirmed COVID-19 case confounders confounding factor COVID-19 Delta delta variant England estimate Factor Hospitalization infections intensive care intrinsic intrinsically invasive ventilation less Lineage Longitudinal data mass Mortality multicenter New occurred omicron outcome outcomes retrospective cohort study risk SARS-CoV-2 secondary severity significantly Vaccinations variant variants variety were excluded with COVID-19 women [DOI] 10.1001/jamanetworkopen.2022.38354 PMC 바로가기
Immunogenicity decay and case incidence six months post Sinovac-CoronaVac vaccine in autoimmune rheumatic diseases patientsArticle Published on 2022-10-032022-11-15 Journal: Nature Communications [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] anti-SARS-CoV-2 anti-TNF antibody Autoimmune booster dose cellular immunity Control COVID-19 case COVID-19 cases cumulative Decline decrease delta variant dose geometric mean titer IgG positivity IgG response Immunity immunogenicity immunosuppressive Inactivated vaccine incidence individuals Logistic regression analysis male multivariate Neutralizing Neutralizing antibodies outcome Patient patients Prednisone Primary outcome reduce reduction in rheumatic disease SARS-CoV-2 IgG SARS-CoV-2 immunity secondary Spread stability Therapies Vaccine vaccine dose [DOI] 10.1038/s41467-022-33042-0 PMC 바로가기
SARS-CoV-2 Secondary Attack Rates in Vaccinated and Unvaccinated Household Contacts during Replacement of Delta with Omicron Variant, SpainArticle Published on 2022-10-012022-11-16 Journal: Emerging Infectious Diseases [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI acute respiratory syndrome attack Contact Contact tracing coronavirus coronavirus disease COVID-19 cross-sectional Delta delta variant household household contact index cases Infection long-lasting Odds ratio omicron Omicron variant performed Probability Rate replacement respiratory infections risk of infection SARS SARS-CoV-2 SARS-COV-2 infection secondary secondary attack rate severe acute respiratory syndrome coronavirus 2 severe disease Spain Spread symptomatic vaccination Vaccine vaccine effectiveness variant viruses zoonoses zoonoses. [DOI] 10.3201/eid2810.220494 PMC 바로가기
Negative predictive value of procalcitonin to rule out bacterial respiratory co-infection in critical covid-19 patientsResearch article Published on 2022-10-012022-10-05 Journal: The Journal of Infection [Category] 바이오마커, 진단, [키워드] added Admission antibiotic Antibiotics association AUC Bacterial bacterial co-infection Biomarker C-reactive protein clinician Co-infection country COVID-19 COVID-19 pneumonia Critical CRP cut-off determine Diagnosis diagnostic evaluate evaluated fungal infections ICU ICU admission Logistic regression Mortality negative Negative predictive value outcome outcomes pandemic Patient patients with COVID-19 PCT Pneumonia predict Predictive procalcitonin Result retrospective cohort study secondary was performed worsening [DOI] 10.1016/j.jinf.2022.06.024 [Article Type] Research article
Activity of ertapenem/zidebactam (WCK 6777) against problem EnterobacteralesArticle Published on 2022-09-302022-11-16 Journal: Journal of Antimicrobial Chemotherapy [Category] SARS, 비임상, [키워드] 1:1 active against activity administration breakpoint Dilution E. coli Escherichia coli evaluated experiments group healthcare increasingly indicated Infection inhibited isolate Klebsiella KPC Laboratory material MDR National nosocomial Outpatient over Parenteral pathogen Patient proportion regimen SARS-CoV-2 secondary submitted Support susceptibility Trial will drive [DOI] 10.1093/jac/dkac280 PMC 바로가기
Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH)Article Published on 2022-09-212022-11-15 Journal: BMC Infectious Diseases [Category] SARS, 진단, 치료기술, [키워드] age analyzed anti-SARS-CoV-2 Anti-spike Antiretroviral therapy black BNT162b2 booster CD4 CD8 cells clinically COVID-19 COVID-19 vaccination COVID-19 vaccine decrease demographics detectable dose exploratory female HIV Humoral immunity IgG IgG levels immune response immunogenicity majority male marker median MOST occurred offered Older outcome participant positive presenting primary analysis protective immunity quantitative assessment reactogenicity recruited responses SARS-CoV-2 SARS-CoV-2. secondary single-center Spike protein subject suppressed T-cell T-cell Response vaccination Viremia virus-specific T-cell response white Wilcoxon signed-rank test with HIV [DOI] 10.1186/s12879-022-07737-0 PMC 바로가기
Rapamycin and inulin for booster vaccine response stimulation (RIVASTIM)-rapamycin: study protocol for a randomised, controlled trial of immunosuppression modification with rapamycin to improve SARS-CoV-2 vaccine response in kidney transplant recipientsArticle Published on 2022-09-152022-11-15 Journal: Trials [Category] SARS, 진단, [키워드] 1:1 binding domain Booster vaccine cell-mediated response clinical Controlled trial COVID COVID-19 COVID-19 vaccination COVID-19 vaccine death develop disease severity dose Effectiveness Efficacy ENhance hospitalisation humoral hypothesise IgG immune cell population immunological Immunosuppression IMPROVE include increased risk Intervention kidney transplant recipient kidney transplant recipients Kidney transplantation live SARS-CoV-2 Modification mTOR inhibitor multicentre neutralisation New outcome participant Prednisolone Primary outcome proportion Protective protective immunity public health randomised randomised controlled trial Rapamycin recipient reduce reduced regimen registry responses SARS-CoV-2 SARS-CoV-2 vaccine secondary serological Sirolimus Standard of care Study protocol Tolerability Trial vaccination vaccination. Vaccine vaccine response virus [DOI] 10.1186/s13063-022-06634-w PMC 바로가기